CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Revenue of CTI BioPharma Corp. (CTIC)
Revenue in 2022 (TTM): $53.95 M
According to CTI BioPharma Corp.'s latest financial reports the company's current revenue (TTM) is $53.95 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of CTI BioPharma Corp.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $53.95 M | $50.43 M | $-79,853,000 | $-92,992,000 | $-91,041,000 |
| 2021 | $ | $-161,000 | $-95,332,000 | $-97,908,000 | $-99,636,000 |
| 2020 | $ | $-4,200,000 | $-47,769,000 | $-52,451,000 | $-52,951,000 |
| 2019 | $3.35 M | $3.35 M | $-37,425,000 | $-40,023,000 | $-42,317,000 |
| 2018 | $26.29 M | $25.41 M | $-32,899,000 | $-29,352,000 | $-29,320,000 |
| 2017 | $25.15 M | $24.78 M | $-39,519,000 | $-40,831,000 | $-40,670,000 |
| 2016 | $57.41 M | $56.03 M | $-49,162,000 | $-52,953,000 | $-52,009,000 |
| 2015 | $16.12 M | $14.18 M | $-116,666,000 | $-120,763,000 | $-119,422,000 |
| 2014 | $60.08 M | $59.18 M | $-86,233,000 | $-94,229,000 | $-93,367,000 |
| 2013 | $34.68 M | $34.54 M | $-39,634,000 | $-43,550,000 | $-42,743,000 |
| 2012 | $ | $ | $-98,972,000 | $-101,687,000 | $-101,374,000 |
| 2011 | $ | $ | $-58,911,000 | $-62,619,000 | $-62,360,000 |
| 2010 | $319 K | $319 K | $-74,755,000 | $-95,395,000 | $-82,642,000 |
| 2009 | $80 K | $80 K | $-81,559,000 | $-95,395,000 | $-95,395,000 |
| 2008 | $11.43 M | $8.19 M | $-77,283,000 | $-180,029,000 | $-180,029,000 |
| 2007 | $127 K | $78 K | $-132,986,000 | $-138,108,000 | $-138,108,000 |
| 2006 | $80 K | $80 K | $-98,600,000 | $-135,819,000 | $-135,819,000 |
| 2005 | $16.09 M | $15.57 M | $-57,733,000 | $-102,505,000 | $-102,505,000 |
| 2004 | $29.59 M | $28.49 M | $-229,876,000 | $-252,298,000 | $-252,298,000 |
| 2003 | $24.77 M | $23.93 M | $-112,265,000 | $-130,031,000 | $-130,031,000 |
| 2002 | $16.9 M | $16.47 M | $-98,787,000 | $-49,903,000 | $-49,903,000 |
| 2001 | $6.24 M | $5.84 M | $-62,048,000 | $-74,285,000 | $-80,273,000 |
| 2000 | $502.04 K | $1.53 M | $-40,951,384 | $-51,384,503 | $-51,928,791 |
| 1999 | $100 K | $2.3 M | $-34,100,000 | $-35,700,000 | $-36,300,000 |
| 1998 | $13.2 M | $15.1 M | $-22,700,000 | $-24,600,000 | $-25,000,000 |
| 1997 | $11.8 M | $13.4 M | $-21,400,000 | $-22,700,000 | $-23,000,000 |
| 1996 | $9.1 M | $-5,200,000 | $-11,600,000 | $-13,400,000 | $-13,900,000 |